Researchers from Anhui Medical University (AMU) and Wuhan University of Technology (WUT) presented the discovery of novel acetylcholinesterase (AChE) inhibitors as potential disease-modifying ...
Patients with dementia aged 50 years or older who continued the use of acetylcholinesterase (AChE) inhibitors had a lower risk for delirium diagnosed during hospitalisation than those who discontinued ...
Cholinesterase inhibition remains a cornerstone of symptomatic therapy for Alzheimer’s disease, targeting the enzymes acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) to restore ...
The investigational agent was designed to reduce the gastrointestinal side effects observed with galantamine. The Food and Drug Administration (FDA) has accepted for review the New Drug Application ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results